GVS debuts on Borsa Italiana’s MTA

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

First listing of the year on the Mercato Telematico Azionario (MTA) of the Italian Stock Exchange

Today, June 19th 2020, GVS lands on the MTA of Borsa Italiana. This is the first new listing of the year on the main market of Borsa Italiana and the second IPO in Europe for the amount raised, equal to 570.5 million Euros, totaling the proceeds deriving from the full exercise of the greenshoe option, and with a free float equal to 40%.

The market capitalization at the IPO price is 1,426 million euros. Through the listing, GVS will be able to consolidate its competitive positioning on global markets and continue on its growth path.

“Today the entry on the Stock Exchange marks another important step in our growth project and represents the recognition of solid foundations built with commitment and passion in 40 years of activity.” – commented Massimo Scagliarini, CEO of GVS – “Our team of over 2400 people all over the world, which fully embraces the values of GVS, has enabled us to achieve this result. GVS has strong Italian roots and operates globally with 20 offices and 14 production plants. We are proud that the financial community has appreciated our business model. The listing on the Stock Exchange is the starting point of a new phase and we are ready to face the new challenges that await us.”

Goldman Sachs International and Mediobanca – Banca di Credito Finanziario SpA acted as joint global coordinators and joint bookrunners, Mediobanca – Banca di Credito Finanziario also acted as Sponsor. Lazard acted as financial advisor to the Company and Alirahealth as independent strategic advisor. White & Case acted as legal advisor to the Company, while Clifford Chance acted as legal advisor to the joint global coordinators and joint bookrunners. The company in charge of the statutory audit of GVS is PricewaterhouseCoopers SpA. Image Building acted as communication advisor.

More To Explore


GVS acquires 100% of the Shanghai Transfusion Technology Co., Ltd

GVS announced that it has entered into a binding agreement with Ningbo Fuji Medical Technology Co., Ltd., a company controlled by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., to acquire the entire share capital of Shanghai Transfusion Technology Co., Ltd., a Shanghai headquartered company active in the production and sale of blood management related products. The


GVS acquires 100% of the Italian Group Haemotronic

GVS has acquired the 100% of the share capital of the Italian Group Haemotronic, a leading supplier of advanced filtration solutions for highly critical applications and a specialized producer of components and bags for the medical sector with plants in Italy and Mexico.  In line with its strategy, the acquisition of the company contributes to

Scroll to Top

Want to explore the global website?

You are currently at GVS Malaysia website. To visit the global website, click the button below.

Email Inquiries Form

We are always here for you! send us a mail now if you have any questions!